We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

5 hedge funds and large institutions have $74K invested in Benitec Biopharma in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,300% more capital invested

Capital invested by funds: $1K → $74K (+$73K)

400% more funds holding

Funds holding: 1 → 5 (+4)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
5
Holders Change
+4
Holders Change %
+400%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WS
Wedbush Securities
California
+$67K
2
AIM
Acrospire Investment Management
Illinois
+$17.7K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$10.1K
4
UBS Group
UBS Group
Switzerland
+$3.16K
5
Deutsche Bank
Deutsche Bank
Germany
+$2.53K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WS
1
Wedbush Securities
California
$50K +$67K +106 New
AIM
2
Acrospire Investment Management
Illinois
$13K +$17.7K +28 New
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$8K +$10.1K +16 New
UBS Group
4
UBS Group
Switzerland
$2K +$3.16K +5 +500%
Deutsche Bank
5
Deutsche Bank
Germany
$1K +$2.53K +4 New

BNTC Hedge Fund Activity: Q2 2017 in Review

5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2017, worth a combined $74K — up 7,300% from $1K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BNTC positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Wedbush Securities, opening a new position worth an estimated $67K.

  • 5 institutional investors held Benitec Biopharma (BNTC) as of Q2 2017, up from 1 in Q1 2017.
  • Funds reported $74K of Benitec Biopharma stock for Q2 2017, up 7,300% quarter-over-quarter.
  • 4 funds opened new Benitec Biopharma positions in Q2 2017 and 0 closed out, a net change of +4 holders.
  • The largest Benitec Biopharma buyer in Q2 2017 was Wedbush Securities, an estimated $67K added.

Based on aggregated 13F filings for Q2 2017.